Regeneron Pharmaceuticals, Inc. Earnings

Regeneron Pharmaceuticals, Inc.’s revenue jumped 0.9% since last year same period to $3754.3Mn in the Q3 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 2.14% jump in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit jumped 8.91% since last year same period to $1460Mn in the Q3 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 4.92% jump in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin jumped 7.93% since last year same period to 38.89% in the Q3 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 2.72% jump in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 9.67 - a 14.71% jump from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 9.67.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Regeneron Pharmaceuticals, Inc. declared 0.88 dividend per share during the earnings announcement for Q3 2025.